Single genetic defect produces specific cognitive deficit in miceSeptember 07, 2006Researchers have found that, in mice, producing a single genetic defect in a molecule that "reloads" neurons to trigger one another using the neurotransmitter acetylcholine impairs the mice's ability to recognize objects or other mice. The researchers, Marco Prado, Marc Caron, Vania Prado, and their colleagues, said their findings reveal a critical role in central nervous system (CNS) function for the component of the reloading machinery, called an acetylcholine transporter, that they knocked out. They also said their findings suggest that the mouse model will be useful in understanding how defects in neurons that use acetylcholine to trigger one another contribute to cognitive decline in such disorders as Alzheimer's disease (AD) and aging. The researchers published their finding in the September 7, 2006, issue of the journal Neuron, published by Cell Press. To explore the role of the acetylcholine transporter, the researchers genetically modified mice to either completely lack the transporter gene or to have reduced levels of it. Such transporters normally retrieve acetylcholine that one neuron has used to trigger another and transport it to storage sacs called vesicles that are the reservoir for neurotransmitter for subsequent use. The researchers found that such transporter-deficient mice were less able to fill such vesicles with acetylcholine. In behavioral tests, the researchers found that the mice with lower levels of the transporter were less able to learn to hang on to a rotating rod than normal mice. Mice completely lacking the transporter were totally unable to manage the task because they lacked physical endurance. Thus, wrote the researchers, those mice might be useful models for studying the effects of reduced acetylcholine release in certain neuromuscular disorders. Both normal mice and those with reduced transporter were equally able to learn and remember to avoid a mild shock. However, the reduced-transporter mice showed deficits in object recognition-significantly less able to remember that they had encountered specific-shaped plastic blocks before. The altered mice also showed less memory of "intruder" mice placed in their cages-evidence of reduced social recognition. Significantly, the researchers found that when they used a drug to enhance acetylcholine in the transporter-deficient mice, those mice showed improved performance on social recognition tests, implying that the deficit in social recognition was caused by a reduction in "cholinergic tone." Prado, Caron, and their colleagues concluded that "Our observations support the notion that reduced cholinergic tone in AD mouse models can indeed cause deficits in social memory. However, based on somewhat similar impairments found in the object and social recognition tasks, it is possible that mild cholinergic deficits may cause a more general memory deficit for recognizing previously learned complex cues, whether social or not. Future detailed investigations will be necessary to further define the specific type of cognitive processing affected by cholinergic deficits in these mutants. "Such studies in mouse models of reduced cholinergic tone may be particularly informative for understanding the contribution of cholinergic decline to specific behavioral alterations observed in certain pathologies of the CNS and may even be helpful in understanding physiological aging,\\\ Cell Press |
|||||||||||||||||||||
| Related Acetylcholine Current Events and Acetylcholine News Articles Genetically-modified mice reveal another mechanism contributing to heart failure Scientists at the Robarts Research Institute at The University of Western Ontario, working in collaboration with researchers in Brazil, have used a unique genetically-modified mouse line to reveal a previously unidentified mechanism contributing to heart failure. New compound improves cognitive decline, symptoms of Alzheimer's disease in rodents A fast-acting compound that appears to improve cognitive function impairments in mice similar to those found in patients with progressive Alzheimer's disease has been identified by scientists at Wake Forest University School of Medicine and the Vanderbilt University Medical Center Program in Drug Discovery. Researchers hope to one day replicate the result in humans. New approach to fighting Alzheimer's shows potential in clinical trial In the early stages of Alzheimer's disease, patients typically suffer a major loss of the brain connections necessary for memory and information processing. New approach to fighting Alzheimer's shows potential in clinical trial In the early stages of Alzheimer's disease, patients typically suffer a major loss of the brain connections necessary for memory and information processing. Now, a combination of nutrients that was developed at MIT has shown the potential to improve memory in Alzheimer's patients by stimulating growth of new brain connections. New biosensors reveal workings of anti-psychotic drugs in the living brain Scientists have resolved a question about how a popular class of drugs used to treat schizophrenia works using biosensors that reveal previously hidden components of chemical communication in the brain. Muscle cell infusion shown to strengthen sphincters in animals in Stanford study A new study shows that muscle cells grown in the lab can restore an intestine's ability to squeeze shut properly. The work, performed in dogs and rats, might ultimately help treat patients with conditions such as gastric reflux and fecal incontinence. New Down syndrome treatment suggested by Stanford/Packard study in mice At birth, children with Down syndrome aren't developmentally delayed. But as they age, these kids fall behind. Memory deficits inherent in Down syndrome hinder learning, making it hard for the brain to collect experiences needed for normal cognitive development. Developmental delay could stem from nicotinic receptor deletion The loss of a gene through deletion of genetic material on chromosome 15 is associated with significant abnormalities in learning and behavior, said a consortium of researchers led by Baylor College of Medicine (www.bcm.edu) in a report that appears online today in the journal Nature Genetics. Risk of abnormally slow heart rate twice as high in those taking drugs to slow Alzheimer's People taking one of several drugs commonly prescribed to treat Alzheimer's disease are more likely to be hospitalized for a potentially serious condition called bradycardia than patients not taking these medications. Promising new treatment for Alzheimer's suggested based on Hebrew University research Research carried out at the Hebrew University of Jerusalem has resulted in a promising approach to help treat Alzheimer's disease in a significant proportion of the population that suffers from a particularly rapid development of this disease. More Acetylcholine Current Events and Acetylcholine News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||